Zentalis Pharmaceuticals, Inc.
ZNTL
$3.87
-$0.16-3.97%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -33.76% | -33.76% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -33.76% | -33.76% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -33.76% | -33.76% |
| SG&A Expenses | -55.30% | -60.78% | -61.45% | 9.99% | 13.61% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -23.67% | -37.17% | -44.73% | -28.19% | -24.52% |
| Operating Income | 11.63% | 28.71% | 24.85% | 27.11% | 22.82% |
| Income Before Tax | 14.83% | 44.87% | 17.55% | 16.51% | 16.15% |
| Income Tax Expenses | 401.72% | 1,552.94% | 149.72% | -183.00% | -176.07% |
| Earnings from Continuing Operations | 14.28% | 44.63% | 17.37% | 16.74% | 16.40% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -100.00% | -100.00% |
| Net Income | 14.28% | 44.63% | 17.35% | 16.72% | 16.37% |
| EBIT | 11.63% | 28.71% | 24.85% | 27.11% | 22.82% |
| EBITDA | 11.44% | 28.58% | 24.73% | 27.08% | 22.83% |
| EPS Basic | 14.06% | 44.78% | 18.15% | 17.51% | 17.08% |
| Normalized Basic EPS | 7.11% | 34.12% | 17.35% | 16.45% | 16.02% |
| EPS Diluted | 14.06% | 44.78% | 18.22% | 17.58% | 17.14% |
| Normalized Diluted EPS | 7.11% | 34.12% | 17.38% | 16.48% | 16.04% |
| Average Basic Shares Outstanding | -0.23% | 0.34% | 1.11% | 1.13% | 0.94% |
| Average Diluted Shares Outstanding | -0.23% | 0.34% | 1.00% | 1.02% | 0.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |